Shareholders urged to contact Wolf Haldenstein Adler Freeman & Herz LLP immediately
Lead Plaintiff deadline is next Tuesday, July 7, 2015
NEW YORK, June 30, 2015 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action has been filed in the United States District Court for the Central District of California on behalf of all persons or entities that purchased the securities of Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE MKT:AMPE) between January 13, 2014 and August 21, 2014, inclusive (the “Class Period). Wolf Haldenstein encourages all shareholders who suffered losses on common stock purchased within the Class Period to contact us immediately at classmember@whafh.com or (800) 575-0735.
According to the filed Complaint, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the clinical research organization conducting the STEP Study lacked independence; (2) the trial drug supply for the STEP Study was shipped to clinical sites at lower temperatures than permitted by the specifications of the drug; and (3) as a result of the foregoing, the Company’s public statements were materially false and misleading and caused the stock to trade at artificially high prices.
On August 21, 2014, the Company issued a press release announcing a delay in the data analysis of the STEP Study due to the discovery by the independent Clinical Research Organization (“CRO”) that the study drugs were, during shipment to the clinical sites, exposed to lower temperatures than permitted by the drug specifications. Then, on August 22, 2014, the blog Buyerstrike issued a report of Ampio, which asserted a number of red flags with the STEP Study.
Shares in Ampio dropped over 35% as a result of these disclosures, closing at $4.84 per share on August 22, 2014, on heavy trading volume.
If you purchased Ampio securities during the Class Period, you may, no later than next Tuesday, July 7, 2015, request that the Court appoint you lead plaintiff of the proposed class. A lead plaintiff is a representative party that acts on behalf of all class members in directing the litigation. Any member of the purported class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has over 70 attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com. All e-mail correspondence should make reference to the “Ampio” Investigation.”
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.